Monica Gandhi
Infectious Disease · San Francisco, CANPI 1396700019
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $46,204 of the $59,931 with a category attached, or 77.1%. 8 manufacturers reported payments, led by Viiv Healthcare Company at 50.9% of the total. 2025 is the largest year on record at $33,207, more than ten times the $250 reported in 2020. Among infectious disease clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 42 payments — averaging $1426.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$30K
- Gilead$13K
- Sanofi Pasteur Inc.$10K
- Merck$4K
- Pfizer$2K
- Janssen Scientific Affairs, LLC$475
- plus $266 from 2 others
Across 7 payments — averaging $81,758 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$572K
What the payments were for
- Royalty or licence$2620%
- Consulting fees$46,20477%
- Speaking & faculty fees$9,97017%
- Grants$1,7133%
- Travel & lodging$1,1032%
- Food & beverage$6601%
- Education$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 9 | $30,477 |
| Gilead | 11 | $12,828 |
| Sanofi Pasteur Inc. | 4 | $10,086 |
| Merck | 12 | $3,563 |
| Pfizer | 2 | $2,237 |
| Janssen Scientific Affairs, LLC | 2 | $475 |
| Johnson & Johnson | 1 | $250 |
| Lightforce Orthodontics, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PAXLOVID$2,237
How this compares
$59,931 in reported general payments places this provider in the 95th percentile of 856 infectious disease providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 54 | $212,869 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 50 | $212,564 |
| TivicayDolutegravir Sodium | 85 | $182,551 |
| CabenuvaCabotegravir/Rilpivirine | 20 | $118,211 |
| PrezcobixDarunavir/Cobicistat | 51 | $114,558 |
| DovatoDolutegravir Sodium/Lamivudine | 24 | $67,691 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 15 | $64,163 |
| DescovyEmtricitabine/Tenofov Alafenam | 20 | $49,257 |
| JulucaDolutegravir/Rilpivirine | 12 | $40,456 |
| PifeltroDoravirine | 23 | $35,929 |
| OzempicSemaglutide | 17 | $15,840 |
| OxycontinOxycodone Hcl | 15 | $13,622 |
| JardianceEmpagliflozin | 16 | $9,492 |
| Maraviroc | 12 | $9,057 |
| EliquisApixaban | 13 | $8,654 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Viiv Healthcare CompanyTriumeq, Tivicay, Cabenuva, Dovato, Juluca | $30,477 | $621,472191 claims |
| GileadBiktarvy, Descovy | $12,828 | $262,12574 claims |
| Johnson & JohnsonPrezcobix | $250 | $114,55851 claims |
| MerckPifeltro | $3,563 | $35,92923 claims |
| PfizerEliquis, Premarin | $2,237 | $12,58826 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 856 infectious disease providers in California.
Other infectious disease in San Francisco
- Shawn HasslerSan Francisco$433K
- Abhijit LimayeSan Francisco$152K
- Joel PalefskySan Francisco$68K
- Claire PomeroySacramento$2.6M
- Javeed SiddiquiRoseville$1.5M
- George SakoulasSan Diego$902K
- Arthur JengSylmar$766K
- James McKinnellTorrance$762K
- Jay GladsteinLos Angeles$657K
- Tulika SinghOrange$654K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.